| Title |
Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis
|
|---|---|
| Published in |
Current Rheumatology Reports, January 2014
|
| DOI | 10.1007/s11926-013-0406-3 |
| Pubmed ID | |
| Authors |
Chantal L. Duurland, Lucy R. Wedderburn |
| Abstract |
Use of biomarkers in clinical practice has proved extremely valuable and is a rapidly expanding field. However, despite the huge potential of biomarkers, for juvenile idiopathic arthritis (JIA) there are currently no validated paediatric biomarkers available to help with setting up a more tailored approach on which drug choice could be based, to achieve remission early in the course of disease. Early remission reduces burden of disease, limits side effects from toxic and unnecessary medication, and, most importantly, enhances quality of life. Several studies have suggested promising biomarkers: these may be a protein, cellular component, mRNA, or genetic component, for example a single nucleotide polymorphism (SNP). Here we describe recent developments in the use of biomarkers for JIA and their potential to assist in management of disease by predicting disease phenotype, severity, progression, and response to treatment, and determining when patients have reached stable remission and can safely discontinue treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 7% |
| Unknown | 14 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 20% |
| Researcher | 2 | 13% |
| Student > Master | 2 | 13% |
| Other | 1 | 7% |
| Professor | 1 | 7% |
| Other | 3 | 20% |
| Unknown | 3 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 20% |
| Biochemistry, Genetics and Molecular Biology | 2 | 13% |
| Immunology and Microbiology | 2 | 13% |
| Agricultural and Biological Sciences | 2 | 13% |
| Arts and Humanities | 1 | 7% |
| Other | 2 | 13% |
| Unknown | 3 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2020.
All research outputs
#6,936,550
of 22,743,667 outputs
Outputs from Current Rheumatology Reports
#242
of 709 outputs
Outputs of similar age
#83,200
of 305,602 outputs
Outputs of similar age from Current Rheumatology Reports
#2
of 13 outputs
Altmetric has tracked 22,743,667 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 709 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,602 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.